|Articles|August 9, 2021
Pharmacy Clinical Pearl of the Day: PrEP for HIV
Author(s)Saro Arakelians, PharmD
Truvada is a medicine people at risk for HIV should take to prevent infection with the virus from various ways, such as sex or injection drug use.
Advertisement
Clinical Pearl of the Day: PrEP for HIV
- Emtricitabine and tenofovir disoproxil fumarate (Truvada) for pre-exposure prophylaxis (PrEP) is a once-daily prescription medicine for adults and adolescents at risk of HIV who weigh at least 77 pounds.
Explanation
- Truvada is a medicine people at risk for HIV should take to prevent infection with the virus from various ways, such as sex or injection drug use.
- PrEP consists of a combination of 2 antiretroviral drugs (tenofovir and emtricitabine), usually taken daily and often in combination with other HIV medicines.
- When taken consistently, the Centers for Disease Control and Prevention estimates that PrEP reduces the risk of HIV infection by up to 92%.
Reference
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5